Holdings of Virtus Biotech Clinical Trials Etf
ETFis Series Trust I · Original filing · Compare with another fund · Report an error
- Net assets
- 37.3M $ including 37.3M $ in equities, 99.9 %
- Positions
- 124 in 8 countries
- Top ten
- 16.2 % of net assets
- Filed on
- Apr 30, 2026
Portfolio shape
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Erasca Inc | 76,668 | 816.5K $ | 2.19 % |
| 2 | Enliven Therapeutics Inc | 16,370 | 674.9K $ | 1.81 % |
| 3 | Tango Therapeutics Inc | 29,518 | 638.2K $ | 1.71 % |
| 4 | Oruka Therapeutics Inc | 9,143 | 625.5K $ | 1.68 % |
| 5 | Spyre Therapeutics Inc | 8,208 | 611.1K $ | 1.64 % |
| 6 | Alumis Inc | 24,020 | 593.1K $ | 1.59 % |
| 7 | Dianthus Therapeutics Inc | 6,551 | 575.2K $ | 1.54 % |
| 8 | Kodiak Sciences Inc | 11,591 | 504K $ | 1.35 % |
| 9 | Revolution Medicines Inc | 3,496 | 503.8K $ | 1.35 % |
| 10 | Corvus Pharmaceuticals Inc | 32,976 | 500.9K $ | 1.34 % |
| 11 | Rezolute Inc | 153,338 | 490.7K $ | 1.31 % |
| 12 | Definium Therapeutics Inc | 21,993 | 481.2K $ | 1.29 % |
| 13 | CG oncology Inc | 6,741 | 449.9K $ | 1.21 % |
| 14 | JADE BIOSCIENCES INC | 18,425 | 449.6K $ | 1.20 % |
| 15 | Inhibrx Biosciences Inc | 3,467 | 448K $ | 1.20 % |
| 16 | Relay Therapeutics Inc | 34,371 | 445.4K $ | 1.19 % |
| 17 | GH RESEARCH PLC | 21,175 | 434.7K $ | 1.16 % |
| 18 | Nektar Therapeutics | 5,045 | 429K $ | 1.15 % |
| 19 | Tyra Biosciences Inc | 12,196 | 423.8K $ | 1.14 % |
| 20 | Vir Biotechnology Inc | 41,256 | 421.4K $ | 1.13 % |
| 21 | Intellia Therapeutics Inc | 30,599 | 412.5K $ | 1.10 % |
| 22 | CENTESSA PHARMACEUTICALS PLC | 10,411 | 410.4K $ | 1.10 % |
| 23 | AnaptysBio Inc | 6,139 | 403.5K $ | 1.08 % |
| 24 | Omeros Corp | 27,192 | 397K $ | 1.06 % |
| 25 | Tectonic Therapeutic Inc | 13,966 | 390.6K $ | 1.05 % |
| 26 | Allogene Therapeutics Inc | 182,788 | 389.3K $ | 1.04 % |
| 27 | Compass Pathways plc | 40,950 | 371K $ | 0.99 % |
| 28 | Edgewise Therapeutics Inc | 11,685 | 361.8K $ | 0.97 % |
| 29 | Palvella Therapeutics Inc | 2,798 | 359K $ | 0.96 % |
| 30 | Capricor Therapeutics Inc | 10,606 | 356.1K $ | 0.95 % |
| 31 | Vaxcyte Inc | 6,201 | 354.9K $ | 0.95 % |
| 32 | Pharvaris NV | 11,424 | 354.3K $ | 0.95 % |
| 33 | ArriVent Biopharma Inc | 11,300 | 351.3K $ | 0.94 % |
| 34 | Xenon Pharmaceuticals Inc | 6,264 | 351K $ | 0.94 % |
| 35 | Neurogene Inc | 13,193 | 344.2K $ | 0.92 % |
| 36 | Summit Therapeutics Inc | 15,708 | 337.1K $ | 0.90 % |
| 37 | Amylyx Pharmaceuticals Inc | 21,068 | 337.1K $ | 0.90 % |
| 38 | Celldex Therapeutics Inc | 10,032 | 329.9K $ | 0.88 % |
| 39 | Praxis Precision Medicines Inc | 1,026 | 327.1K $ | 0.88 % |
| 40 | Arcus Biosciences Inc | 12,819 | 326.9K $ | 0.88 % |
| 41 | Annexon Inc | 55,535 | 326K $ | 0.87 % |
| 42 | Terns Pharmaceuticals Inc | 6,132 | 324.6K $ | 0.87 % |
| 43 | Liquidia Corp | 8,268 | 324.2K $ | 0.87 % |
| 44 | Monte Rosa Therapeutics Inc | 16,922 | 324.1K $ | 0.87 % |
| 45 | Immunome Inc | 14,102 | 323.5K $ | 0.87 % |
| 46 | Bicara Therapeutics Inc | 14,934 | 322.3K $ | 0.86 % |
| 47 | Celcuity Inc | 2,621 | 318.1K $ | 0.85 % |
| 48 | Ironwood Pharmaceuticals Inc | 77,097 | 318K $ | 0.85 % |
| 49 | AbCellera Biologics Inc | 76,245 | 316.4K $ | 0.85 % |
| 50 | Precigen Inc | 74,799 | 311.2K $ | 0.83 % |
| 51 | Belite Bio Inc | 1,952 | 310.7K $ | 0.83 % |
| 52 | Beam Therapeutics Inc | 10,087 | 305.9K $ | 0.82 % |
| 53 | MoonLake Immunotherapeutics | 18,661 | 305.7K $ | 0.82 % |
| 54 | Taysha Gene Therapies Inc | 47,669 | 304.6K $ | 0.82 % |
| 55 | Cullinan Therapeutics Inc | 23,153 | 302.1K $ | 0.81 % |
| 56 | IMMATICS NV | 27,490 | 302.1K $ | 0.81 % |
| 57 | Rapport Therapeutics Inc | 9,118 | 302.1K $ | 0.81 % |
| 58 | Zymeworks Inc | 10,832 | 298.3K $ | 0.80 % |
| 59 | Apogee Therapeutics Inc | 3,580 | 296.7K $ | 0.79 % |
| 60 | Prothena Corp PLC | 26,642 | 294.7K $ | 0.79 % |
| 61 | ORIC Pharmaceuticals Inc | 29,424 | 290.7K $ | 0.78 % |
| 62 | Denali Therapeutics Inc | 15,351 | 287.4K $ | 0.77 % |
| 63 | Protagonist Therapeutics Inc | 2,894 | 286.4K $ | 0.77 % |
| 64 | MeiraGTx Holdings plc | 30,942 | 285.3K $ | 0.76 % |
| 65 | Immunovant Inc | 10,446 | 283.6K $ | 0.76 % |
| 66 | Rocket Pharmaceuticals Inc | 81,418 | 283.3K $ | 0.76 % |
| 67 | uniQure NV | 14,147 | 282.2K $ | 0.76 % |
| 68 | Soleno Therapeutics Inc | 5,306 | 280.3K $ | 0.75 % |
| 69 | MBX Biosciences Inc | 9,242 | 279.3K $ | 0.75 % |
| 70 | Stoke Therapeutics Inc | 8,521 | 278.8K $ | 0.75 % |
| 71 | Cytokinetics Inc | 4,355 | 278.6K $ | 0.75 % |
| 72 | CytomX Therapeutics Inc | 65,872 | 278K $ | 0.74 % |
| 73 | Scholar Rock Holding Corp | 5,888 | 274.4K $ | 0.74 % |
| 74 | AtaiBeckley Inc | 64,337 | 267.6K $ | 0.72 % |
| 75 | Nuvalent Inc | 2,633 | 264K $ | 0.71 % |
| 76 | Janux Therapeutics Inc | 18,038 | 259.2K $ | 0.69 % |
| 77 | Septerna Inc | 10,849 | 257.8K $ | 0.69 % |
| 78 | Dyne Therapeutics Inc | 14,322 | 251.4K $ | 0.67 % |
| 79 | Sionna Therapeutics Inc | 6,453 | 249.7K $ | 0.67 % |
| 80 | Kymera Therapeutics Inc | 3,077 | 249.5K $ | 0.67 % |
| 81 | Arbutus Biopharma Corp | 58,600 | 246.1K $ | 0.66 % |
| 82 | Nurix Therapeutics Inc | 14,473 | 241.7K $ | 0.65 % |
| 83 | Prime Medicine Inc | 67,319 | 238.6K $ | 0.64 % |
| 84 | ProKidney Corp | 124,892 | 237.3K $ | 0.64 % |
| 85 | ENGENE THERAPEUTICS INC | 32,625 | 237.2K $ | 0.64 % |
| 86 | Ideaya Biosciences Inc | 8,112 | 236.1K $ | 0.63 % |
| 87 | Xeris Biopharma Holdings Inc | 38,494 | 235.8K $ | 0.63 % |
| 88 | Cogent Biosciences Inc | 6,554 | 234.6K $ | 0.63 % |
| 89 | Viking Therapeutics Inc | 7,443 | 232.1K $ | 0.62 % |
| 90 | Biohaven Ltd | 23,938 | 229.6K $ | 0.61 % |
| 91 | EyePoint Inc | 17,260 | 227.8K $ | 0.61 % |
| 92 | 4D Molecular Therapeutics Inc | 25,461 | 225.8K $ | 0.60 % |
| 93 | Recursion Pharmaceuticals Inc | 63,742 | 220.5K $ | 0.59 % |
| 94 | Arvinas Inc | 21,940 | 217.2K $ | 0.58 % |
| 95 | Newamsterdam Pharma Co NV | 7,408 | 211.6K $ | 0.57 % |
| 96 | Savara Inc | 39,885 | 209K $ | 0.56 % |
| 97 | Assembly Biosciences Inc | 7,645 | 206K $ | 0.55 % |
| 98 | Xencor Inc | 16,707 | 199.3K $ | 0.53 % |
| 99 | Mineralys Therapeutics Inc | 7,478 | 199.3K $ | 0.53 % |
| 100 | Disc Medicine Inc | 3,004 | 198.1K $ | 0.53 % |
Sector breakdown
- Unattributed 100.0 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- United States 86.3 %
- Canada 3.7 %
- Netherlands 3.1 %
- Cayman Islands 2.4 %
- Ireland 2.0 %
- United Kingdom 1.6 %
- British Virgin Islands 0.6 %
- Singapore 0.3 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | United States | 106 | 32.2M $ | 86.34 % |
| 2 | Canada | 4 | 1.4M $ | 3.72 % |
| 3 | Netherlands | 4 | 1.2M $ | 3.08 % |
| 4 | Cayman Islands | 3 | 901.6K $ | 2.42 % |
| 5 | Ireland | 2 | 729.4K $ | 1.96 % |
| 6 | United Kingdom | 3 | 580K $ | 1.55 % |
| 7 | British Virgin Islands | 1 | 229.6K $ | 0.62 % |
| 8 | Singapore | 1 | 117.7K $ | 0.32 % |
Cite this page
Titelia. "Holdings of Virtus Biotech Clinical Trials Etf". https://titelia.com/en/funds/S000047353